Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
252.33B
Market cap252.33B
Price-Earnings ratio
28.95
Price-Earnings ratio28.95
Dividend yield
2.13%
Dividend yield2.13%
Average volume
2.57M
Average volume2.57M
High today
$469.00
High today$469.00
Low today
$461.00
Low today$461.00
Open price
$465.98
Open price$465.98
Volume
1.83M
Volume1.83M
52 Week high
$475.65
52 Week high$475.65
52 Week low
$288.00
52 Week low$288.00

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $466.74. The company's market cap stands at 252.33B, with a P/E ratio of 28.95 and a dividend yield of 2.13%.

On 2026-11-02, Amgen(AMGN) stock moved within a range of $461.00 to $469.00. With shares now at $466.74, the stock is trading +1.2% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 1.83M, compared to an average daily volume of 2.57M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $475.65 and a low of $288.00.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $475.65 and a low of $288.00.

AMGN News

Seeking Alpha 2h
Amgen Q3 preview: What to expect

Analysts will be keenly tracking the top-line performance of Amgen’s (AMGN) established products, as they continue to see revenue erosion, when the firm reports...

Amgen Q3 preview: What to expect
The Motley Fool 2h
Amgen Just Gave Its Shareholders Great News

This year has been a tremendous one for healthcare company Amgen (AMGN -0.22%), as it has risen by more than 40% in value thus far. While a lot of the hype in h...

Amgen Just Gave Its Shareholders Great News
TipRanks 3h
Amgen Advances Otezla Dosing Study as Investors Watch for a Simpler Formulation

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. (AMGN) is preparing a Phase 1 study titled “A Phase 1, Open-la...

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

Zacks 3h
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?

The third-quarter 2026 reporting cycle for the Medical sector is in full swing, with most companies having already reported their results and several others sch...

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
Simply Wall St 11h
Amgen Could Be 29% Overvalued Following Encouraging Phase 3 Trial Data

Fresh trial data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis has put Amgen (AMGN) back in the spotlight for...

Amgen Could Be 29% Overvalued Following Encouraging Phase 3 Trial Data
Simply Wall St 1d
How Positive Trial Results At Amgen Have Changed Its Investment Story

Amgen reported in late October 2026 that Phase 3 data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis showed st...

The Motley Fool 2d
Looking For Growth, Income, and Stability? This Stock Could Offer All 3

Investment styles come in various shapes and sizes. Some focus on growth, others seek regular income through dividends, and others are after stability. The choi...

Looking For Growth, Income, and Stability? This Stock Could Offer All 3
Simply Wall St 3d
Amgen Stock Could Trade At A Discount To Cash Flow

has delivered a powerful share price run in recent years, yet the question for investors today is whether that higher tag is properly underpinned by the cash th...

24/7 Wall St. 3d
How to Build $6,800 a Month in Dividend Income Without Selling a Single Share

Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which comp...

How to Build $6,800 a Month in Dividend Income Without Selling a Single Share
24/7 Wall St. 4d
Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?

Investing Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming? Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report th...

Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.